Rodriguez-Vida, AlejoStrijbos, Michiel H.Hutson, Thomas Xavier2017-12-222017-12-222017Rodriguez-Vida A, Strijbos M, Hutson T. Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. ESMO Open. 2016 May 25;1(3):e000013. DOI: 10.1136/esmoopen-2015-0000132059-7029http://hdl.handle.net/10230/33562In the past decade, several agents targeting angiogenesis and signal transduction pathways have replaced the use of cytokines as standard of care treatment for metastatic renal cell carcinoma (RCC) after showing improved clinical benefit and survival. Currently, several novel immunotherapy agents targeting the programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) pathways are being tested in metastatic RCC and are bound to revolutionise the management of this disease. However, the success of both antiangiogenic drugs and new immunotherapy agents still depends on our ability to select patients most likely to respond to treatment. This article will review the current available evidence on prognostic and predictive biomarkers of response to signal transduction pathways-targeted agents and modern immunotherapy in metastatic RCC.application/pdfeng© Rodriguez-Vida A.“This article was published in BMJ Open following peer review and can also be viewed on the journal’s website at http://bmjopen.bmj.com” This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ImmunoteràpiaTimosinaMarcadors bioquímicsinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1136/esmoopen-2015-000013BiomarkerImmunotherapyProgrammed cell death-1Renal cell carcinomaTyrosine kinase inhibitorinfo:eu-repo/semantics/openAccess